APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Receptor ROR-Gamma

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nuclear Receptor ROR-Gamma Market Analysis and Forecast 2026-2032

19 December 2025206 pages

Choose your research edition.

Industry ResearchNuclear Receptor ROR-Gamma Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Receptor ROR-Gamma Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Nuclear Receptor ROR-Gamma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Receptor ROR-Gamma Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Receptor ROR-Gamma Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Nuclear Receptor ROR-Gamma market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nuclear Receptor ROR-Gamma include 4SC AG, Vitae Pharmaceuticals, Inc., Visionary Pharmaceuticals, Inc., Teijin Pharma Limited, Reata Pharmaceuticals, Inc., Phenex Pharmaceuticals AG, Nuevolution AB, Lead Pharma Holding B.V. and Karo Bio AB, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nuclear Receptor ROR-Gamma, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nuclear Receptor ROR-Gamma, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Receptor ROR-Gamma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nuclear Receptor ROR-Gamma revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nuclear Receptor ROR-Gamma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nuclear Receptor ROR-Gamma revenue, projected growth trends, production technology, application and end-user industry.

Nuclear Receptor ROR-Gamma Segment by Company

4SC AG

Vitae Pharmaceuticals, Inc.

Visionary Pharmaceuticals, Inc.

Teijin Pharma Limited

Reata Pharmaceuticals, Inc.

Phenex Pharmaceuticals AG

Nuevolution AB

Lead Pharma Holding B.V.

Karo Bio AB

Hanmi Pharmaceuticals, Co. Ltd.

GlaxoSmithKline Plc

Genfit SA

Genentech, Inc.

Celgene Corporation

Bristol-Myers Squibb Company

Brickell Biotech, Inc.

Biogen, Inc.

Aurigene Discovery Technologies Limited

Arrien Pharmaceuticals, LLC

Advinus Therapeutics Ltd.

Nuclear Receptor ROR-Gamma Segment by Type

BBI-6000

GSK-2981278

INV-17

VPR-66

Others

Nuclear Receptor ROR-Gamma Segment by Application

Hospital

Clinic

Others

Nuclear Receptor ROR-Gamma Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Receptor ROR-Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Receptor ROR-Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Receptor ROR-Gamma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nuclear Receptor ROR-Gamma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nuclear Receptor ROR-Gamma company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Receptor ROR-Gamma revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nuclear Receptor ROR-Gamma Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. BBI-6000 Major Player Table 3. GSK-2981278 Major Player Table 4. INV-17 Major Player Table 5. VPR-66 Major Player Table 6. Others Major Player Table 7. Global Nuclear Receptor ROR-Gamma Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Clinic Major Player Table 10. Others Major Player Table 11. Nuclear Receptor ROR-Gamma Industry Trends Table 12. Nuclear Receptor ROR-Gamma Industry Drivers Table 13. Nuclear Receptor ROR-Gamma Industry Opportunities and Challenges Table 14. Nuclear Receptor ROR-Gamma Industry Restraints Table 15. Global Nuclear Receptor ROR-Gamma Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nuclear Receptor ROR-Gamma Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nuclear Receptor ROR-Gamma Market Share by Region (2021-2026) Table 18. Global Nuclear Receptor ROR-Gamma Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nuclear Receptor ROR-Gamma Market Share by Region (2027-2032) Table 20. Global Nuclear Receptor ROR-Gamma Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Players (2021-2026) Table 22. Global Nuclear Receptor ROR-Gamma Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nuclear Receptor ROR-Gamma Key Players Headquarters & Area Served Table 24. Global Nuclear Receptor ROR-Gamma Players, Product Type & Application Table 25. Global Nuclear Receptor ROR-Gamma Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nuclear Receptor ROR-Gamma by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nuclear Receptor ROR-Gamma Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Type (2021-2026) Table 32. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Type (2027-2032) Table 33. Global Nuclear Receptor ROR-Gamma Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Application (2021-2026) Table 37. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Application (2027-2032) Table 38. 4SC AG Company Information Table 39. 4SC AG Business Overview Table 40. 4SC AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. 4SC AG Nuclear Receptor ROR-Gamma Product Portfolio Table 42. 4SC AG Recent Development Table 43. Vitae Pharmaceuticals, Inc. Company Information Table 44. Vitae Pharmaceuticals, Inc. Business Overview Table 45. Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 47. Vitae Pharmaceuticals, Inc. Recent Development Table 48. Visionary Pharmaceuticals, Inc. Company Information Table 49. Visionary Pharmaceuticals, Inc. Business Overview Table 50. Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 52. Visionary Pharmaceuticals, Inc. Recent Development Table 53. Teijin Pharma Limited Company Information Table 54. Teijin Pharma Limited Business Overview Table 55. Teijin Pharma Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Teijin Pharma Limited Nuclear Receptor ROR-Gamma Product Portfolio Table 57. Teijin Pharma Limited Recent Development Table 58. Reata Pharmaceuticals, Inc. Company Information Table 59. Reata Pharmaceuticals, Inc. Business Overview Table 60. Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 62. Reata Pharmaceuticals, Inc. Recent Development Table 63. Phenex Pharmaceuticals AG Company Information Table 64. Phenex Pharmaceuticals AG Business Overview Table 65. Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Product Portfolio Table 67. Phenex Pharmaceuticals AG Recent Development Table 68. Nuevolution AB Company Information Table 69. Nuevolution AB Business Overview Table 70. Nuevolution AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Nuevolution AB Nuclear Receptor ROR-Gamma Product Portfolio Table 72. Nuevolution AB Recent Development Table 73. Lead Pharma Holding B.V. Company Information Table 74. Lead Pharma Holding B.V. Business Overview Table 75. Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Product Portfolio Table 77. Lead Pharma Holding B.V. Recent Development Table 78. Karo Bio AB Company Information Table 79. Karo Bio AB Business Overview Table 80. Karo Bio AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Karo Bio AB Nuclear Receptor ROR-Gamma Product Portfolio Table 82. Karo Bio AB Recent Development Table 83. Hanmi Pharmaceuticals, Co. Ltd. Company Information Table 84. Hanmi Pharmaceuticals, Co. Ltd. Business Overview Table 85. Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Product Portfolio Table 87. Hanmi Pharmaceuticals, Co. Ltd. Recent Development Table 88. GlaxoSmithKline Plc Company Information Table 89. GlaxoSmithKline Plc Business Overview Table 90. GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Product Portfolio Table 92. GlaxoSmithKline Plc Recent Development Table 93. Genfit SA Company Information Table 94. Genfit SA Business Overview Table 95. Genfit SA Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Genfit SA Nuclear Receptor ROR-Gamma Product Portfolio Table 97. Genfit SA Recent Development Table 98. Genentech, Inc. Company Information Table 99. Genentech, Inc. Business Overview Table 100. Genentech, Inc. Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Genentech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 102. Genentech, Inc. Recent Development Table 103. Celgene Corporation Company Information Table 104. Celgene Corporation Business Overview Table 105. Celgene Corporation Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Celgene Corporation Nuclear Receptor ROR-Gamma Product Portfolio Table 107. Celgene Corporation Recent Development Table 108. Bristol-Myers Squibb Company Company Information Table 109. Bristol-Myers Squibb Company Business Overview Table 110. Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Product Portfolio Table 112. Bristol-Myers Squibb Company Recent Development Table 113. Brickell Biotech, Inc. Company Information Table 114. Brickell Biotech, Inc. Business Overview Table 115. Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 117. Brickell Biotech, Inc. Recent Development Table 118. Biogen, Inc. Company Information Table 119. Biogen, Inc. Business Overview Table 120. Biogen, Inc. Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Biogen, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 122. Biogen, Inc. Recent Development Table 123. Aurigene Discovery Technologies Limited Company Information Table 124. Aurigene Discovery Technologies Limited Business Overview Table 125. Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Product Portfolio Table 127. Aurigene Discovery Technologies Limited Recent Development Table 128. Arrien Pharmaceuticals, LLC Company Information Table 129. Arrien Pharmaceuticals, LLC Business Overview Table 130. Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Product Portfolio Table 132. Arrien Pharmaceuticals, LLC Recent Development Table 133. Advinus Therapeutics Ltd. Company Information Table 134. Advinus Therapeutics Ltd. Business Overview Table 135. Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Product Portfolio Table 137. Advinus Therapeutics Ltd. Recent Development Table 138. North America Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026) & (US$ Million) Table 139. North America Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032) & (US$ Million) Table 140. North America Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026) & (US$ Million) Table 144. North America Nuclear Receptor ROR-Gamma Revenue by Country (US$ Million) & (2027-2032) Table 145. Europe Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Europe Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026) & (US$ Million) Table 151. Europe Nuclear Receptor ROR-Gamma Revenue by Country (US$ Million) & (2027-2032) Table 152. China Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026) & (US$ Million) Table 153. China Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032) & (US$ Million) Table 154. China Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026) & (US$ Million) Table 155. China Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032) & (US$ Million) Table 156. Asia Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026) & (US$ Million) Table 159. Asia Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Nuclear Receptor ROR-Gamma Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Asia Nuclear Receptor ROR-Gamma Revenue by Region (US$ Million) & (2021-2026) Table 162. Asia Nuclear Receptor ROR-Gamma Revenue by Region (US$ Million) & (2027-2032) Table 163. SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026) & (US$ Million) Table 164. SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032) & (US$ Million) Table 165. SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026) & (US$ Million) Table 166. SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032) & (US$ Million) Table 167. SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026) & (US$ Million) Table 169. SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (US$ Million) & (2027-2032) Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Nuclear Receptor ROR-Gamma Image Figure 2. Global Nuclear Receptor ROR-Gamma Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Receptor ROR-Gamma Market Size Share 2021 VS 2025 VS 2032 Figure 4. BBI-6000 Image Figure 5. GSK-2981278 Image Figure 6. INV-17 Image Figure 7. VPR-66 Image Figure 8. Others Image Figure 9. Global Nuclear Receptor ROR-Gamma Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Nuclear Receptor ROR-Gamma Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Clinic Image Figure 13. Others Image Figure 14. Global Nuclear Receptor ROR-Gamma Market Size (US$ Million) & (2021-2032) Figure 15. Global Nuclear Receptor ROR-Gamma Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nuclear Receptor ROR-Gamma Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nuclear Receptor ROR-Gamma Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nuclear Receptor ROR-Gamma Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nuclear Receptor ROR-Gamma Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Type (2021-2032) Figure 22. Global Nuclear Receptor ROR-Gamma Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nuclear Receptor ROR-Gamma Revenue Market Share by Application (2021-2032) Figure 25. North America Nuclear Receptor ROR-Gamma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032) Figure 27. North America Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032) Figure 28. North America Nuclear Receptor ROR-Gamma Revenue Share by Country (2021-2032) Figure 29. United States Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nuclear Receptor ROR-Gamma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032) Figure 34. Europe Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032) Figure 35. Europe Nuclear Receptor ROR-Gamma Revenue Share by Country (2021-2032) Figure 36. Germany Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nuclear Receptor ROR-Gamma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032) Figure 46. China Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032) Figure 47. Asia Nuclear Receptor ROR-Gamma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032) Figure 49. Asia Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032) Figure 50. Asia Nuclear Receptor ROR-Gamma Revenue Share by Region (2021-2032) Figure 51. Japan Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nuclear Receptor ROR-Gamma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032) Figure 59. SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032) Figure 60. SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Country (2021-2032) Figure 61. Brazil Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nuclear Receptor ROR-Gamma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • BBI-6000
  • GSK-2981278
  • INV-17
  • VPR-66
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • 4SC AG
  • Vitae Pharmaceuticals, Inc.
  • Visionary Pharmaceuticals, Inc.
  • Teijin Pharma Limited
  • Reata Pharmaceuticals, Inc.
  • Phenex Pharmaceuticals AG
  • Nuevolution AB
  • Lead Pharma Holding B.V.
  • Karo Bio AB
  • Hanmi Pharmaceuticals, Co. Ltd.
  • GlaxoSmithKline Plc
  • Genfit SA
  • Genentech, Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Brickell Biotech, Inc.
  • Biogen, Inc.
  • Aurigene Discovery Technologies Limited
  • Arrien Pharmaceuticals, LLC
  • Advinus Therapeutics Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nuclear Receptor ROR-Gamma Market by Type
  3. 1.2.1 Global Nuclear Receptor ROR-Gamma Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 BBI-6000
  5. 1.2.3 GSK-2981278
  6. 1.2.4 INV-17
  7. 1.2.5 VPR-66
  8. 1.2.6 Others
  9. 1.3 Nuclear Receptor ROR-Gamma Market by Application
  10. 1.3.1 Global Nuclear Receptor ROR-Gamma Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Clinic
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nuclear Receptor ROR-Gamma Market Dynamics
  1. 2.1 Nuclear Receptor ROR-Gamma Industry Trends
  2. 2.2 Nuclear Receptor ROR-Gamma Industry Drivers
  3. 2.3 Nuclear Receptor ROR-Gamma Industry Opportunities and Challenges
  4. 2.4 Nuclear Receptor ROR-Gamma Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nuclear Receptor ROR-Gamma Market Perspective (2021-2032)
  2. 3.2 Global Nuclear Receptor ROR-Gamma Growth Trends by Region
  3. 3.2.1 Global Nuclear Receptor ROR-Gamma Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nuclear Receptor ROR-Gamma Market Size by Region (2021-2026)
  5. 3.2.3 Global Nuclear Receptor ROR-Gamma Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nuclear Receptor ROR-Gamma Revenue by Players
  2. 4.1.1 Global Nuclear Receptor ROR-Gamma Revenue by Players (2021-2026)
  3. 4.1.2 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nuclear Receptor ROR-Gamma Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nuclear Receptor ROR-Gamma Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nuclear Receptor ROR-Gamma Key Players Headquarters & Area Served
  7. 4.4 Global Nuclear Receptor ROR-Gamma Players, Product Type & Application
  8. 4.5 Global Nuclear Receptor ROR-Gamma Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nuclear Receptor ROR-Gamma Market CR5 and HHI
  11. 4.6.3 2025 Nuclear Receptor ROR-Gamma Tier 1, Tier 2, and Tier 3
5 Nuclear Receptor ROR-Gamma Market Size by Type
  1. 5.1 Global Nuclear Receptor ROR-Gamma Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nuclear Receptor ROR-Gamma Revenue by Type (2021-2032)
  3. 5.3 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Type (2021-2032)
6 Nuclear Receptor ROR-Gamma Market Size by Application
  1. 6.1 Global Nuclear Receptor ROR-Gamma Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nuclear Receptor ROR-Gamma Revenue by Application (2021-2032)
  3. 6.3 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 4SC AG
  2. 7.1.1 4SC AG Company Information
  3. 7.1.2 4SC AG Business Overview
  4. 7.1.3 4SC AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  5. 7.1.4 4SC AG Nuclear Receptor ROR-Gamma Product Portfolio
  6. 7.1.5 4SC AG Recent Developments
  7. 7.2 Vitae Pharmaceuticals, Inc.
  8. 7.2.1 Vitae Pharmaceuticals, Inc. Company Information
  9. 7.2.2 Vitae Pharmaceuticals, Inc. Business Overview
  10. 7.2.3 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  12. 7.2.5 Vitae Pharmaceuticals, Inc. Recent Developments
  13. 7.3 Visionary Pharmaceuticals, Inc.
  14. 7.3.1 Visionary Pharmaceuticals, Inc. Company Information
  15. 7.3.2 Visionary Pharmaceuticals, Inc. Business Overview
  16. 7.3.3 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  18. 7.3.5 Visionary Pharmaceuticals, Inc. Recent Developments
  19. 7.4 Teijin Pharma Limited
  20. 7.4.1 Teijin Pharma Limited Company Information
  21. 7.4.2 Teijin Pharma Limited Business Overview
  22. 7.4.3 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Product Portfolio
  24. 7.4.5 Teijin Pharma Limited Recent Developments
  25. 7.5 Reata Pharmaceuticals, Inc.
  26. 7.5.1 Reata Pharmaceuticals, Inc. Company Information
  27. 7.5.2 Reata Pharmaceuticals, Inc. Business Overview
  28. 7.5.3 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  30. 7.5.5 Reata Pharmaceuticals, Inc. Recent Developments
  31. 7.6 Phenex Pharmaceuticals AG
  32. 7.6.1 Phenex Pharmaceuticals AG Company Information
  33. 7.6.2 Phenex Pharmaceuticals AG Business Overview
  34. 7.6.3 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Product Portfolio
  36. 7.6.5 Phenex Pharmaceuticals AG Recent Developments
  37. 7.7 Nuevolution AB
  38. 7.7.1 Nuevolution AB Company Information
  39. 7.7.2 Nuevolution AB Business Overview
  40. 7.7.3 Nuevolution AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nuevolution AB Nuclear Receptor ROR-Gamma Product Portfolio
  42. 7.7.5 Nuevolution AB Recent Developments
  43. 7.8 Lead Pharma Holding B.V.
  44. 7.8.1 Lead Pharma Holding B.V. Company Information
  45. 7.8.2 Lead Pharma Holding B.V. Business Overview
  46. 7.8.3 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Product Portfolio
  48. 7.8.5 Lead Pharma Holding B.V. Recent Developments
  49. 7.9 Karo Bio AB
  50. 7.9.1 Karo Bio AB Company Information
  51. 7.9.2 Karo Bio AB Business Overview
  52. 7.9.3 Karo Bio AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Karo Bio AB Nuclear Receptor ROR-Gamma Product Portfolio
  54. 7.9.5 Karo Bio AB Recent Developments
  55. 7.10 Hanmi Pharmaceuticals, Co. Ltd.
  56. 7.10.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
  57. 7.10.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
  58. 7.10.3 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
  60. 7.10.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
  61. 7.11 GlaxoSmithKline Plc
  62. 7.11.1 GlaxoSmithKline Plc Company Information
  63. 7.11.2 GlaxoSmithKline Plc Business Overview
  64. 7.11.3 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Product Portfolio
  66. 7.11.5 GlaxoSmithKline Plc Recent Developments
  67. 7.12 Genfit SA
  68. 7.12.1 Genfit SA Company Information
  69. 7.12.2 Genfit SA Business Overview
  70. 7.12.3 Genfit SA Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Genfit SA Nuclear Receptor ROR-Gamma Product Portfolio
  72. 7.12.5 Genfit SA Recent Developments
  73. 7.13 Genentech, Inc.
  74. 7.13.1 Genentech, Inc. Company Information
  75. 7.13.2 Genentech, Inc. Business Overview
  76. 7.13.3 Genentech, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Genentech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  78. 7.13.5 Genentech, Inc. Recent Developments
  79. 7.14 Celgene Corporation
  80. 7.14.1 Celgene Corporation Company Information
  81. 7.14.2 Celgene Corporation Business Overview
  82. 7.14.3 Celgene Corporation Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Celgene Corporation Nuclear Receptor ROR-Gamma Product Portfolio
  84. 7.14.5 Celgene Corporation Recent Developments
  85. 7.15 Bristol-Myers Squibb Company
  86. 7.15.1 Bristol-Myers Squibb Company Company Information
  87. 7.15.2 Bristol-Myers Squibb Company Business Overview
  88. 7.15.3 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Product Portfolio
  90. 7.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 7.16 Brickell Biotech, Inc.
  92. 7.16.1 Brickell Biotech, Inc. Company Information
  93. 7.16.2 Brickell Biotech, Inc. Business Overview
  94. 7.16.3 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  96. 7.16.5 Brickell Biotech, Inc. Recent Developments
  97. 7.17 Biogen, Inc.
  98. 7.17.1 Biogen, Inc. Company Information
  99. 7.17.2 Biogen, Inc. Business Overview
  100. 7.17.3 Biogen, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Biogen, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  102. 7.17.5 Biogen, Inc. Recent Developments
  103. 7.18 Aurigene Discovery Technologies Limited
  104. 7.18.1 Aurigene Discovery Technologies Limited Company Information
  105. 7.18.2 Aurigene Discovery Technologies Limited Business Overview
  106. 7.18.3 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Product Portfolio
  108. 7.18.5 Aurigene Discovery Technologies Limited Recent Developments
  109. 7.19 Arrien Pharmaceuticals, LLC
  110. 7.19.1 Arrien Pharmaceuticals, LLC Company Information
  111. 7.19.2 Arrien Pharmaceuticals, LLC Business Overview
  112. 7.19.3 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Product Portfolio
  114. 7.19.5 Arrien Pharmaceuticals, LLC Recent Developments
  115. 7.20 Advinus Therapeutics Ltd.
  116. 7.20.1 Advinus Therapeutics Ltd. Company Information
  117. 7.20.2 Advinus Therapeutics Ltd. Business Overview
  118. 7.20.3 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
  120. 7.20.5 Advinus Therapeutics Ltd. Recent Developments
8 North America
  1. 8.1 North America Nuclear Receptor ROR-Gamma Revenue (2021-2032)
  2. 8.2 North America Nuclear Receptor ROR-Gamma Revenue by Type (2021-2032)
  3. 8.2.1 North America Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026)
  4. 8.2.2 North America Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032)
  5. 8.3 North America Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032)
  6. 8.4 North America Nuclear Receptor ROR-Gamma Revenue by Application (2021-2032)
  7. 8.4.1 North America Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026)
  8. 8.4.2 North America Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032)
  9. 8.5 North America Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032)
  10. 8.6 North America Nuclear Receptor ROR-Gamma Revenue by Country
  11. 8.6.1 North America Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026)
  13. 8.6.3 North America Nuclear Receptor ROR-Gamma Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Nuclear Receptor ROR-Gamma Revenue (2021-2032)
  2. 9.2 Europe Nuclear Receptor ROR-Gamma Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032)
  5. 9.3 Europe Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nuclear Receptor ROR-Gamma Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032)
  9. 9.5 Europe Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nuclear Receptor ROR-Gamma Revenue by Country
  11. 9.6.1 Europe Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nuclear Receptor ROR-Gamma Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Nuclear Receptor ROR-Gamma Revenue (2021-2032)
  2. 10.2 China Nuclear Receptor ROR-Gamma Revenue by Type (2021-2032)
  3. 10.2.1 China Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026)
  4. 10.2.2 China Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032)
  5. 10.3 China Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032)
  6. 10.4 China Nuclear Receptor ROR-Gamma Revenue by Application (2021-2032)
  7. 10.4.1 China Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026)
  8. 10.4.2 China Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032)
  9. 10.5 China Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nuclear Receptor ROR-Gamma Revenue (2021-2032)
  2. 11.2 Asia Nuclear Receptor ROR-Gamma Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032)
  5. 11.3 Asia Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nuclear Receptor ROR-Gamma Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032)
  9. 11.5 Asia Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nuclear Receptor ROR-Gamma Revenue by Country
  11. 11.6.1 Asia Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nuclear Receptor ROR-Gamma Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nuclear Receptor ROR-Gamma Revenue (2021-2032)
  2. 12.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country
  11. 12.6.1 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst